Welcome to our dedicated page for Therma Bright news (Ticker: TBRIF), a resource for investors and traders seeking the latest updates and insights on Therma Bright stock.
Therma Bright Inc. reports developments as a developer and investment partner in advanced diagnostic and medical device technologies. Recurring updates center on commercialization of the Venowave™ mobile compression device, including distribution relationships, follow-on unit orders, and use cases in vascular care, post-surgical recovery, circulation support, and DVT prevention.
The company also issues portfolio updates involving Inretio’s PREVA™ Neuro-Thrombectomy System and InStatin’s inhaled statin programs for respiratory disease. Other news categories include board changes, warrant-related capital actions, shareholder-meeting matters, and market expansion through U.S. healthcare distribution channels.
Therma Bright (OTCQB: TBRIF) announced a follow-on commercial order: Horizon Health purchased an additional 100 Venowave™ units after an initial 100-unit shipment delivered in late March 2026. The repeat order reflects reported clinical satisfaction and supports deployment across Horizon's vascular patient base.
Horizon moves over 35,000 compression products annually; both companies will monitor patient outcomes and supply chain efficiency as they anticipate larger, more frequent orders through the year.
Therma Bright (OTCQB: TBRIF) announced a strategic commercial order for an initial 100 Venowave™ units from Horizon Health on March 31, 2026. Horizon prescribes over 3,000 compression products per month, giving Venowave a distribution pathway into U.S. vascular recovery markets.
Therma Bright completed a 2025 proof-of-concept and is also exploring cosmetic wellness applications for lymphatic drainage and post-procedure recovery; further details will follow in a dedicated update.
Therma Bright (OTCQB: TBRIF) announced that portfolio company Inretio completed the first cohort of its First-in-Human study for the PREVA™ Neuro-Thrombectomy System and received positive DSMB review to continue enrollment.
Inretio is pursuing a U.S. IDE and a multi-center pivotal trial planned to conclude within 24 months while scaling manufacturing and advancing a capital raise.
Therma Bright (OTCQB: TBRIF) received a follow-on order of 200 Venowave™ VW5 units from Texas distributor Gen-X Med on January 20, 2026. The shipment expands a distribution relationship after an initial rollout and targets post-surgical recovery for specialized knee procedures among top-tier orthopedic surgeons in the U.S. Gen-X Med cites patient and provider preference for mobile, at-home compression vs. tethered devices. The release cites industry data showing the global compression therapy market was $4.18B in 2024 and is projected to reach $6.72B by 2033 (CAGR 7.30%).
Therma Bright (OTCQB: TBRIF) reports progress at investee InStatin through Dec 18, 2025: the company has designated COPD as its lead clinical indication while retaining asthma in development plans, advanced a new lead molecule INS-102 with improved pharmacokinetics and longer lung residence in preclinical PK studies, and filed a provisional patent on novel inhaled statin formulations.
InStatin strengthened its team and advisory board, is pursuing a $35 million funding round in 2026 to reach proof-of-concept, and is engaging partners for inhaled delivery development with deferred payments pending funding.
Therma Bright (OTCQB: TBRIF) announced on October 10, 2025 the appointment of Michael Raimondo to its Board of Directors, elevating him from the advisory board. Raimondo is a 30-year US healthcare sales and operations veteran who the company says has led over $500 million in sales contracts and held senior commercial roles at Abbott.
Raimondo currently serves as Commercial Lead for Delphine Diagnostics and as Managing Partner at The Potentia Group; he said his focus will be building an internal sales team and expanding reseller channels to accelerate sales of Venowave, Therma Bright's flagship medical device. The company also announced the resignation of board member Alex Saringer.
Therma Bright (OTCQB:TBRIF) has expanded its strategic partnership with Gen-X Med for the distribution of Venowave™ VW5 devices. This follows an initial 200-unit sale announced in April 2025, targeting specialized knee surgeons in the U.S. healthcare network.
The partnership focuses on the growing specialized knee surgery market segment, with Gen-X Med reporting positive patient outcomes from the initial deployment. The global compression therapy market, valued at $4.18 billion in 2024, is projected to reach $6.72 billion by 2033, growing at a CAGR of 7.30%.
Therma Bright (OTCQB: TBRIF) has announced plans to amend the exercise price of 6,250,000 post-consolidation common share purchase warrants. The company proposes to reduce the exercise price from $0.80 to $0.06 per share for warrants issued during a Private Placement in June 2024.
Of the total warrants, 1,162,500 are held by company insiders, but due to TSXV policies, only 625,000 insider-held warrants will be eligible for repricing. The warrants maintain their original expiry dates of June 10 and June 20, 2027. Additionally, the company has received approval to postpone its 2025 annual general meeting to November 2025.
Therma Bright (OTCQB: TBRIF) has announced a significant 1:8 share consolidation effective July 8, 2025. The company's outstanding shares will be reduced from 454,457,147 to approximately 56,807,143 shares post-consolidation.
The consolidation will affect all outstanding incentive stock options and warrants, which will be adjusted proportionally. Shareholders will receive new share certificates or Direct Registration Advice after submitting their pre-consolidation certificates with a letter of transmittal to Olympia Trust Company.